032940.Kq

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.17, indicating a relatively low reliance on debt financing. However, its liquidity position is assessed as medium, with a current ratio of 0.93, suggesting that the company's current assets are slightly less than its current liabilities. The company's free cash flow of 2,646,092,950 KRW indicates a positive cash flow from operations after capital expenditures, which supports its operational flexibility.

In terms of profitability, the company's return on equity (ROE) is 4.05%, and its return on assets (ROA) is 3.01%. These figures are below the industry median for ROE and ROA, indicating that the company's profitability is lagging compared to its peers. The company's operating income of 8,699,264,190 KRW and net income of 11,501,783,680 KRW reflect a solid performance, but the gross profit margin of 47.7% suggests that the company is facing competitive pressures or cost inefficiencies.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration increases the company's exposure to market-specific risks, particularly in its primary operating region. The company's revenue of 150,734,965,460 KRW is derived from its core operations in medical equipment, supplies, and distribution, with no material contributions from other business lines.

The company's growth trajectory is expected to remain stable, with no significant changes in revenue or earnings projected for the current fiscal year. The company's capital expenditure of -11,281,579,040 KRW indicates a reduction in investment in physical assets, which may signal a strategic shift towards cost optimization or a focus on operational efficiency. The company's operating cash flow of 1,086,643,240 KRW supports its ability to fund operations and meet short-term obligations.

The company's risk assessment indicates a medium liquidity risk, primarily due to its current ratio being below 1.0, and a low dilution risk, as there is no indication of significant share issuance or dilution potential. The company's net cash position is negative after subtracting total debt, which could impact its ability to fund future growth initiatives without external financing. The company's risk profile is further influenced by its exposure to the healthcare sector, which is subject to regulatory changes and market volatility.

Recent events and disclosures indicate that the company has maintained a consistent financial performance, with no material changes in its business operations or strategic direction. The company's last actual EPS was reported at 2,577.00 KRW, reflecting a stable earnings performance. The company's financial statements and disclosures do not indicate any significant legal or regulatory issues that could impact its operations or financial position.